Menu

Final Nail Hammered into NgAgo Coffin

The paper describing the gene-editing method is retracted.

Aug 3, 2017
Kerry Grens

ISTOCK, FSTOP123Following an editorial expression of concern last year, the authors of a study describing a gene-editing method have retracted their paper from Nature Biotechnology. They say that despite the efforts of numerous independent laboratories, their observations could not be replicated.

The editors of Nature Biotechnology praised the process. “[I]t is the wider research community that tests methods, identifies potential sources of error, validates reagents and optimizes assays,” they wrote in an editorial. “In this case, it took dozens of dedicated individuals to work through the details of the published protocol and produce well-documented and controlled refutation studies.”

The original study claimed to have found a competitor for CRISPR genome editing. NgAgo, an Argonaut protein from archaea, could precisely disrupt specified sequences in the human genome, Chunyu Han of Hebei University of Science and Technology in Shijiazhuang, China, and colleagues reported. But replication attempts failed.

“We are therefore retracting our initial report at this time to maintain the integrity of the scientific record,” Han’s team wrote in the retraction notice. “We nevertheless continue to investigate the reasons for this lack of reproducibility with the aim of providing an optimized protocol.”

See “Scientists Can’t Replicate Gene-Editing Method

As Nature points out, Danish biomedical company Novozymes paid an undisclosed amount of money to partner with Hebei. “Scientific research takes time and we’ll continue to look for any technological advances, NgAgo included, that can have a positive impact on our work,” Dongyi Chen, Novozymes’s press manager, tells Nature.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.